Disease | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Malignant tumor of colon
|
0.100 | GeneticVariation | BEFREE | The clinical studies in the manuscript by Al-Marrawi et al. describe the rational combination of signaling inhibitors in a colon cancer patient whose tumor cells express a mutant active B-RAF V600E protein that signals into the MEK1/2-ERK1/2 pathway downstream of K-RAS; this is a particularly aggressive form of colon cancer for which few rational therapeutic interventions have been available until recent times. | 24025253 | 2013 | |||||
Malignant tumor of colon
|
0.100 | GeneticVariation | BEFREE | Colon cancers carrying BRAF V600E and β-catenin T41A activating mutations are resistant to numerous common anticancer drugs. | 29541216 | 2018 | |||||
Malignant tumor of colon
|
0.100 | GeneticVariation | BEFREE | The results of these studies suggest that combined treatment of BRAF(V600E)-driven colon cancers with both vemurafenib and EGFR inhibitors is worth clinical evaluation. | 23074264 | 2012 | |||||
Malignant tumor of colon
|
0.100 | GeneticVariation | BEFREE | Most BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon cancers are intrinsically resistant to these drugs because of feedback activation of EGFR. | 26365186 | 2015 | |||||
Malignant tumor of colon
|
0.100 | GeneticVariation | BEFREE | In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR). | 24670642 | 2014 | |||||
Malignant tumor of colon
|
0.100 | GeneticVariation | BEFREE | Colon cancers from 2008 to 2012 tested by pyrosequencing for BRAF V600E mutation were selected. | 23650027 | 2013 | |||||
Malignant tumor of colon
|
0.100 | GeneticVariation | BEFREE | In conclusion, our findings suggest that targeting ErbB-3 receptors could represent an effective therapeutic approach in BRAF-V600E mutant colon cancer. | 26160848 | 2015 | |||||
Malignant tumor of colon
|
0.100 | GeneticVariation | BEFREE | Sorafenib and cetuximab therapy led to a mixed radiographic response with some areas showing dramatic improvement and other areas showing stable disease over a 7-month period which is a notably long period of progression-free survival for V600E BRAF mutated colon cancer. | 23792568 | 2013 | |||||
Malignant tumor of colon
|
0.100 | GeneticVariation | BEFREE | Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors. | 22281684 | 2012 | |||||
Malignant tumor of colon
|
0.100 | GeneticVariation | BEFREE | Female patients and older group harbored a higher KRAS mutation (P = 0.018 and P = 0.031, respectively); BRAF (V600E) mutation showed a higher frequency in colon cancer and poor differentiation tumors (P = 0.020 and P = 0.030, respectively); proximal tumors appeared a higher PIK3CA mutation (P<0.001) and distant metastatic tumors shared a higher NRAS mutation (P = 0.010). | 24339949 | 2013 | |||||
Malignant tumor of colon
|
0.100 | GeneticVariation | BEFREE | Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. | 28951457 | 2017 |